Executive Order 14357: Modifying Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China

What does Executive Order 14357 do?

This action formed part of the 2025–2026 tariff framework. On February 20, 2026, the Supreme Court held that IEEPA does not authorize presidential tariffs; EO 14389 then ended the additional ad valorem duties imposed under the listed IEEPA orders. Measures based on other statutes and the all-country de minimis suspension require separate analysis.

Reading the operative provisions of Executive Order 14357

EO 14357 reduced the additional China duty associated with the synthetic-opioid supply-chain emergency after a bilateral arrangement. It adjusted a temporary tariff measure; it did not remove every duty on Chinese goods or change the underlying customs classification system. The Federal Register text of EO 14357 sets the rate and effective period.

The action linked trade measures to the administration’s stated efforts to address fentanyl and precursor chemicals. A tariff is a customs measure on imported goods; it is not itself a criminal penalty on a foreign government or an assessment of whether a particular company trafficked drugs. The bilateral arrangement and the order’s tariff terms should be distinguished from law-enforcement cooperation and public-health responses.

The temporary rate later ended or was displaced by subsequent tariff actions, so EO 14357 is recorded as completed or expired. Importers must apply the rate in force on the date of entry and check other duties that may apply. Its historical record shows how the administration used trade policy in the negotiations, but it does not establish current tariff liability or whether the bilateral commitments were fully met.